The first peptide with human clinical trials available
Know the science behind Pepnow
iScience · 2026 · Human clinical trial
Effects of RMH™ Peptide | Pep-19™ on Adipose Tissue Distribution and Metabolic Parameters in Adults with Obesity
Vantini D, de Sá JR, Sarni ROS, et al.
The study
A 90-day randomized, double-blind, placebo-controlled trial in 56 adults with obesity. Participants took a daily oral placebo or Pep-19 at 5 mg or 10 mg, and researchers tracked where body fat was stored along with key metabolic markers.
Key findings
- At 10 mg, central (belly) fat decreased: the android-to-gynoid fat ratio went down and abdominal skinfold thickness was reduced.
- These changes happened without changes in body weight, calorie intake, or physical activity.
- HbA1c and HOMA-IR fell significantly while fasting glucose was unchanged, pointing to improved insulin sensitivity.
What it means
The authors conclude that Pep-19 shifted fat distribution in a favourable direction and improved insulin sensitivity without significant weight loss, and they call for larger, longer-term studies.
Summary written by Pepnow from the published paper. Results are from individual studies and do not guarantee individual outcomes. See our Medical Disclaimer.
Effects of RMH™ Peptide | Pep-19™ on Adipose Tissue Distribution and Metabolic Parameters in Adults with Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
iScience
2026
Diabetes/Metabolism Research and Reviews · Human clinical trial
RMH™ Peptide | Pep-19™: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults
Heimann AS, Singh P, Ferro ES, Greenway F, Krongrad A
The study
An early-stage, placebo-controlled, triple-blinded trial in 24 adults aged 46–59 with a BMI of 30–35. For 60 days, participants took a placebo or a 2 mg or 5 mg Pep-19 capsule once daily at bedtime. The main measure was quality of life; researchers also measured weight, visceral fat (by DEXA scan), and waist, hip and chest size.
Key findings
- Pep-19 was well tolerated, with no adverse effects reported.
- The 5 mg group lost about 17% of its visceral fat.
- Participants reported improved sleep quality.
What it means
The authors note that the small sample, short duration and convenience sampling limit how far the results can be generalised, but they describe Pep-19 as a promising new approach to reducing visceral fat and improving sleep.
Summary written by Pepnow from the published paper. Results are from individual studies and do not guarantee individual outcomes. See our Medical Disclaimer.
RMH™ Peptide | Pep-19™: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults—Results From an Early-Stage Clinical Trial
Diabetes Metabolism Research and Reviews
2026
The Veterinary Journal · 2024 · Safety study
Safety of White Adipose Tissue Activator Cyclophilin A Intracellular Peptide (RMH™ Peptide | Pep-19™) in Healthy Dogs
Murphy M, Rollins AW, Heimann AS, Fang J, Krongrad A
The study
Eight healthy adult beagles received 5 mg of Pep-19 by mouth once a day for 28 days while eating their usual diet. Researchers ran health checks, blood work and urinalysis at the start, at day 14 and at day 28, and monitored appetite and condition every day.
Key findings
- No adverse effects were observed, and all blood and urine results stayed normal.
- With no change in diet or calories, seven of the eight dogs lost between 0.7% and 3.8% of their body weight.
- Body condition scores also improved.
What it means
The authors conclude that Pep-19 is safe for dogs at this dose and recommend further research into its use for reducing excess body fat.
Summary written by Pepnow from the published paper. Results are from individual studies and do not guarantee individual outcomes. See our Medical Disclaimer.
Safety of white adipose tissue activator cyclophilin A intracellular peptide (RMH™ Peptide | Pep-19™) in healthy dogs
The Veterinary Journal
2024
International Journal of Molecular Sciences · 2022 · Preclinical study
RMH™ Peptide | Pep-19™ Has a Positive Effect on Insulin Sensitivity and Ameliorates Both Hepatic and Adipose Tissue Phenotype of Diet-Induced Obese Mice
Silvério R, Barth R, Heimann AS, et al.
The study
Mice fed either a standard or a high-fat diet received Pep-19 (1 mg/kg) or a saline control by mouth once a day for 30 days. Researchers then assessed metabolism, tissue structure and behaviour.
Key findings
- Pep-19 reduced weight gain in mice on the high-fat diet and improved how well insulin levels matched insulin sensitivity.
- It reduced liver inflammation and fat build-up in the liver, and lowered ALT, a marker of liver stress.
- White fat showed signs of “browning”: brown-fat-like cells appeared and UCP1 expression increased.
- No changes in behaviour were seen.
What it means
The authors conclude that oral Pep-19 improved several metabolic traits disrupted by diet-induced obesity in this mouse model.
Summary written by Pepnow from the published paper. Results are from individual studies and do not guarantee individual outcomes. See our Medical Disclaimer.
RMH™ Peptide | Pep-19™ Has a Positive Effect on Insulin Sensitivity and Ameliorates Both Hepatic and Adipose Tissue Phenotype of Diet-Induced Obese Mice
International Journal of Molecular Sciences
2022
Scientific Reports · 2017 · Discovery study
A Novel Peptide That Improves Metabolic Parameters Without Adverse Central Nervous System Effects
Reckziegel P, Festuccia WT, Britto LRG, et al.
The study
This is the paper that first identified Pep-19, a 10-amino-acid peptide (DIIADDEPLT) that acts on the cannabinoid type 1 (CB1) receptor. The researchers tested it in fat cells and in rats made obese through diet.
Key findings
- Pep-19 increased UCP1, a marker of fat “browning”, in fat cells and white fat tissue.
- Taken by mouth, it reduced body fat, body weight, glucose, triglycerides, cholesterol and blood pressure in obese rats, without changing heart rate.
- There were no signs of effects on the brain or behaviour, including no anxiety- or depression-like behaviour.
What it means
The authors suggest Pep-19 has advantages over earlier compounds that act on this receptor and could have clinical applications.
Summary written by Pepnow from the published paper. Results are from individual studies and do not guarantee individual outcomes. See our Medical Disclaimer.
A novel peptide that improves metabolic parameters without adverse central nervous system effects
Scientific Reports
2017
Experience metabolic optimization today
Transform high-risk fat into energy with a research-backed formula designed for physical integrity.
Experience metabolic optimization today
Transform high-risk fat into energy with a research-backed formula designed for physical integrity.
